期刊文献+

奈达铂联合氟尿嘧啶持续静滴治疗晚期食管癌临床疗效观察 被引量:2

Clinical observation of nedaplatin combined with 5-fluorouracil intravenous infusion in the treatment of advanced squamous-cell carcinoma of esophagus
下载PDF
导出
摘要 目的观察奈达铂联合5-Fu持续静滴治疗晚期食管癌的疗效和不良反应。方法晚期食管鳞癌患者27例,奈达铂80~100mg/m2加入生理盐水500ml中静滴2h;5-Fu0.25g/(m2.d),静脉滴注24h,第1~14天。28d为1周期,连用2个周期后评价疗效。结果全组27例均可评价疗效及不良反应,总有效率55.6%。其中初治者19例,部分缓解12例,有效率63.2%;复治者8例,部分缓解3例,有效率37.5%。主要不良反应为骨髓抑制,4例(14.8%)患者出现Ⅲ~Ⅳ度血小板下降,7例(25.9%)患者出现Ⅲ~Ⅳ度白细胞降低。消化道反应轻,未发现肝肾功能损害。结论奈达铂联合5-Fu持续静滴治疗晚期食管癌疗效肯定,不良反应小,可代替顺铂作为治疗晚期食管癌的一线方案,对顺铂耐药的患者亦有一定的疗效。 Objective To evaluate efficacy and toxic effects of nedaplatin plus 5-fluorouracil intravenouss infusion in treatment of advanced squamous-cell carcinoma of esophagus. Methods A total of 27 patients with advanced squamous-cell carcinoma of esophagus were selected and nedaplatin was administered at a dose of 80 -100 mg/m^2 with 500ml of saline by drip infusion for 2 hours on day 1 ,and 5-fluorouracil at a dose of 0. 25 g/( m^2 · day) given by intravenous drip over 24 hours on days 1 to 14. The chemotherapy was repeatedly given every 28 days and the efficacy was evaluated after 2 cycles of treatment. Results Response and toxicity could be assessed in all the 27 patients. The overall response rate was 55.6% ,of 19 patients who had not received chemotherapy previously, 12 showed partial response,with a response rate of 63. 2%. Of 8 patients previously treated with cisplatin and 5-fluorouraci1,3 showed partial response, with a response rate of 37. 5%. The major toxic reaction was myelosuppression, in which grade Ⅲ-Ⅳ thrombocytopenia was observed in 4 patients( 14. 8% ) and grade Ⅲ-Ⅳ neutropenia in 7 patients( 25.9% ). Gastrointestinal toxic reaction was mild and renal or hepatic toxicity was not observed. Conclusions The combined chemotherapy with nedaplatin and 5-fluorouracil can be considered as the first-line regimen in the treatment of advanced squamous-cell carcinoma of esophagus, in which nedaplatin may be a substitute for cisplatin. It is effective not only for the patients having not received chemotherapy previously, but also for those resistant to cisplatin. This regimen is effective and well tolerated.
出处 《中国肿瘤临床与康复》 2008年第3期229-231,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 食管肿瘤/化学疗法 奈达铂 5-FU Esophageal neoplasms/chemotherapy Nedaplatin 5-Fluorouracil
  • 相关文献

参考文献7

二级参考文献9

共引文献110

同被引文献15

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2Yoshioka T,Gamoh M,Shineha R,et al.A new combination chemotherapy with cis-diammine-glycolatinum (Nedaplatin) and 5-Fu for advanced esophageal cancers[J].Inter Med,1999,38(11):844-848.
  • 3Ratain M J, Mick R, Schilsky RL, et al. Statistical and ethica| issues in the design and conduct of phase I and II clinical trials of new anticancer agents[J].J Natl Cancer Inst, 1993,85(20): 1637-1643.
  • 4Nakamura T, Ide H, Eguchi R, et al. Nedaplatin and 5- fluorouracil combined with radiotherapy for advanced esophageal cancer[J]. Gan To Kagaku Ryoho,2003,30(6): 803-807.
  • 5Yoshioka T, Sakayori M, Kato S, et al. Dose escalation study of docetaxel and nedaplatin in patients with re- lapsed or refractory squamous cell carcinoma of the esophagus pretreated using radiation[J].Int J Clin Oncol, cisplatin 5-fluorouracil, and 2006,11 (6):454-460.
  • 6Kawai Y, Taniuchi S, Okahara S,et al. Relationship be- tween cisplatin or nedaplatin-induced nephrotoxicity and re- nal accumulation[J].Biol Pharm Bu11,2005,28(8):.1385-1388.
  • 7Desoize B,Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment[J].Crit Rev Oneol Hematol, 2002,42(3):317-325.
  • 8Hamnann JT,Lipp Hp.Toxicity of platinum compounds[J]. Expert Opin Pharmacother,2003,4(6):889-897.
  • 9Nemoto K,Matsushita H,Ogawa Y, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer[J].Am J Clin 0ncol,2003,26(l):46-49.
  • 10Jingu K,Nemoto K,Matsushita H. et al. Results of radia- tion therapy combined with nedaplatin (cis-diammine-gly- coplatinum) and 5-fluorouracil for postoperative locore- gional recurrent esophageal cancer [J].BMC Cancer, 2006,6:50.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部